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Background: Prolactin is a hormone; in addition to it known roles, it has immunomodulatory effects on lym-
phocytes maturation and immunoglobulins production. Hyperprolactinemia has been demonstrated in
various autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes
mellitus, and Graves’ disease. In view of the prolactin immunomodulatory roles, studying prolactin levels
in pemphigus as an autoimmune blistering disease may introduce new ways of understanding disease eti-
ology and developing treatment strategies.
Objective: Our purpose was to determine the prolactin levels in patients with newly diagnosed pemphigus
vulgaris and study its correlation with pemphigus disease area index.
Limitation: Our study was limited by the lack of a control group.
Methods: In this cross-sectional study, prolactin and anti-desmoglein 1 and 3 autoantibodies levels were
measured in 50 patients with newly diagnosed pemphigus vulgaris in Razi Dermatology Hospital. Pemphi-
gus severity and extent was estimated using the Pemphigus Disease Area Index.
Results:Of the 50 patients, 18weremale and 32were femalewith amean age of 41.56± 13.66 years.Mean
prolactin (PRL) level was 15.60 ± 11.72 ng/ml (10.68 in males and 18.37 in females). Mean anti-
desmoglein 1 and 3 autoantibodies were 135.8 ± 119.8 and 245.8 ± 157.4 U/ml, respectively. Eleven out
of 50 patients had a higher than normal prolactin range. No relation was found between prolactin level
and disease activity (p = .982). Also, correlation studies show no relation between prolactin and anti-
desmoglein 1 and 3 autoantibodies levels (respectively, p=.771 and .738). In comparing the extent of the dis-
ease between the two groupswith normal and high prolactin, paired t-test showed no signiﬁcance (p=.204).
Conclusion: In our study, 22% of patients had hyperprolactinemia, which was greater among females. The
highest PRL level was detected in mucocutaneous group. Although serum PRL levels were higher in patients
with a greater Pemphigus Disease Area Index, it did not reach statistical signiﬁcance.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prolactin (PRL) is a hormone mainly secreted from the anterior
pituitary under the inhibition of dopamine and involved in
lactogenesis. PRL is also produced in other sites, such as cells of the
immune system. In addition to production by immune cells, prolactin
has receptors on monocytes, macrophages, natural killer cells, and T
and mainly B lymphocytes. In the last decades, studies have shown).
c. on behalf of Women's Dermatimmunomodulatory effects of PRL on lymphocyte maturation and
immunoglobulin production (De Bellis et al., 2005; Draca, 1995;
Ignacak et al., 2012; Jara et al., 2011; Orbach and Shoenfeld, 2007;
Shelly et al., 2012; Vera-Lastra et al., 2002).
Hyperprolactinemia has been demonstrated in autoimmune dis-
eases, such as systemic lupus erythematosus, rheumatoid arthritis,
type I diabetes mellitus, Graves’ disease, and multiple sclerosis (De
Bellis et al., 2005; Draca, 1995; Ignacak et al., 2012; Jara et al., 2011;
Moshirzadeh et al., 2012; Orbach and Shoenfeld, 2007; Shelly et al.,
2012; Vera-Lastra et al., 2002). Some correlation has been described
between lupus activity and PRL levels (Rezaieyazdi and Hesamifard,ologic Society. This is an open access article under the CC BY-NC-ND license (http://
Table 2
PRL levels among PV subtypes.
Pemphigus Type No. of Patients Prolactin Levels
ng/ml
(Mean ± SD)
Hyperprolactinemia
PRL levels>23.3 ng/ml for
Females
PRL levels>15.2 ng/ml for
Males
Mucocutaneous 31 15.77 ± 11.25 9
Mucuosal 11 17.62 ± 16.48 1
Cutaneous 8 12.18 ± 3.43 1
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onist has been effective for some autoimmune diseases (Alvarez-
Nemegyei et al., 1998; McMurray, 2001).
Pemphigus is a group of autoimmune blistering diseases, inwhich
functional inhibition of desmoglein (Dsg) 1 and 3 by autoantibodies
results in loss of cell-cell adhesion.
Despite vast research on pathophysiology of pemphigus, the exact
causes of autoantibodies are unknown.
Khandpur and Reddy (2002) reported a case of new onset pem-
phigus vulgaris (PV) and idiopathic hyperprolactinemia that was re-
sponsive to steroid and bromocriptine treatment. Other studies have
shown a correlation between PRL level and PV (Barzegari et al., 2004;
Fallahzadeh et al., 2010; Helmy et al., 2013; Kavala et al., 2006).
In view of the prolactin immunomodulatory roles, further studies
of prolactin levels in a pemphigus patient and its correlationwith dis-
ease severity may introduce new ways of understanding disease eti-
ology and developing treatment strategies.
Method and materials
All newpatients diagnosedwith PV in Autoimmune Bullous Diseases
Research Center, Razi Hospital, Tehran University of Medical Sciences,
Iran, between 2011 and 2012 were included in this case series. PV diag-
nosis was made by both pathologic and immunoﬂuorescence studies.
Pregnancy or lactation; presence of renal, hepatic, or chest wall
disease; recent abortion; taking antipsychotic or estrogen containing
drugs; and use of opioids were exclusion criteria for this study.
Blood samples were collected before starting corticosteroid ther-
apy and stored in laboratory at –70 °C. After collection completion,
PRL levels were measured in the samples by chemiluminescence im-
munoassay (Cobas kits, Elecsys device). Anti-Dsg 1 and 3 autoanti-
bodies levels were also measured in all patients as another disease
activity index by enzyme-linked immunosorbent assay.
We used PemphigusDisease Area Index (PDAI) as ameasurement
index of disease activity, which has 3 components relating to the skin,
scalp, and mucous membranes. Activity score is a value given to the
number of erosions, blisters, or new erythema at the time of exami-
nation. The maximum total score is 263, consisting of 250 points for
the activity and 13 for damage scores (Daniel et al., 2012).
All data were analyzed using the Statistical Package for Social Sci-
ences software (SPSS, Chicago, IL, version 20). The correlation
between prolactin levels and the extent of involvement was studied
by a Spearman test. A t-test was used to compare the extent of in-
volvement in groups with normal and high PRL levels.
Results
Fifty patients were included in the study: 18 were male and 32
were female with a mean age of 41.56 (±13.66) years. Mean PRL
level was 15.60± 11.72 ng/ml (10.68 inmales and 18.37 in females).Table 1
PRL levels among age groups.
Age Groups
(years old)
No. of Patients Prolactin
Levels
ng/ml
(Mean ± SD)
Hyperprolactinemia
PRL levels>23.3 ng/ml for Females
PRL levels>15.2 ng/ml for Males
10-20 4 19.58 ± 14.86 2 (50%)
20-30 5 16.97 ± 10.78 2 (40%)
30-40 13 17.63 ± 18.51 3 (23.1%)
40-50 16 13.15 ± 6.91 1 (6.3%)
50-60 8 15.95 ± 8.34 2 (25%)
60-70 2 14.79 ± 1.03 1 (50%)
70-80 2 10.09 ± 2.22 0
Total 50 15.60 ± 11.72 11 (22%)To study PRL levels according to age, patients were divided into
seven age groups. Eleven out of 50 patients (eight females and three
males) had PRL higher than normal (Table 1). Thirty-one patients
hadmucocutaneous, 11 patients had onlymucuosal, and eight patients
had only cutaneous as the site of involvement (Table 2).
Mean anti-Dsg 1 and 3 autoantibodies levels were 135.8 ± 119.8
and 245.8 ± 157.4 U/ml, respectively (laboratory range: negative
≤14 and positive ≥ 20). Based on PDAI, mean index was 19.76 ±
14.07 with a range of 3 to 63.
No relation was found between PRL level and disease activity by
Spearman test, neither totally (p= .982) nor among gender groups
separately with p= .582 for female group and .592 for male group.
The average extent of involvement in the group with high PRL
was 25.72, 18.07 in the group with normal PRL. Paired t-test showed
no signiﬁcant difference in disease extent between patients with nor-
mal PRL and those with high PRL (p= .204).
The mean extent of involvement among men with high and nor-
mal PRL were 20.33 and 20.55, respectively. Women showed a
mean extent of 27.75 in the group with high PRL levels and 16.54 in
the group with normal levels of PRL. Similarly, paired t-test with
p= .997 among men and .175 among women did not show any sig-
niﬁcant association.
No signiﬁcant relation was found between PRL level and cutane-
ous, mucosal, or mucocutaneous subtypes; p values were 0.247,
0.904, and 0.601, respectively.
Anti-Dsg 3 levels had signiﬁcant correlation with PDAI (p= .01).
Anti-Dsg 1 and 3 levels correlation with PRL levels were nonsigniﬁ-
cant (p= .771 and .738, respectively).
Kolmogorov–Smirnov testwas applied to study thedistribution of
the extent of involvement and was normal.
Discussion
In the past 2 decades, studies have revealed extrapituitary sources
of PRL as well as its immunoregulatory role.
Hyperprolactinemia has been observed in some autoimmune dis-
eases such as systemic lupus erythematosus, rheumatoid arthritis,
type I diabetes mellitus, and Graves’ thyroiditis. Vesiculobullous skin
diseases, like the pemphigus group, have an autoimmune etiology.
Research has been conducted on hyperprolactinemia prevalence
and its correlation with disease activity in patients with pemphigus.
Barzegar et al.’s (2004) study of 44 patients with autoimmune blister-
ing skin disease showed signiﬁcantly higher prolactin levels in compar-
ison to control group. Kavala et al. (2006) reported signiﬁcantly
increasing PRL levels during active phases of the disease compared to
the control group in bothmale and female patients (p b .05 and b .01).
Helmy et al.’s (2013) study fromEgypt showed no statistically sig-
niﬁcant difference between serum PRL levels in PV patients and con-
trols. The highest serum PRL level was detected in patients with
mucocutaneous involvement, followed by those with mucosal in-
volvement, and was the least in those with cutaneous involvement.
However, there was no statistically signiﬁcant difference among the
three types. A highly signiﬁcant correlation was found between PRL
level and the extent of body surface involvement.
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levels of PV patients were signiﬁcantly higher than those in the control
group (p= .048), and there was a positive correlation between serum
prolactin levels and extent of disease (Fallahzadeh et al., 2010).
Some animal and human studies show stress-induced prolactin
rise (Noel et al, 1972; Schedlowski et al, 1992; Seggie and Brown,
1975). On the other hand, quality of life studies on blistering diseases
describe impairments and psychological distress among pemphigus
patients (Ghodsi et al, 2012).
In our study, 22% of patients had hyperprolactinemia, which was
greater among females. The highest PRL level was detected in the mu-
cocutaneous group, followed by the cutaneous and then the mucosal
groups. Comparison among these three groups showedno signiﬁcance,
which is in concordancewith the results of Helmy et al.’s (2013) study.
Althoughwe could not ﬁnd statistically signiﬁcant correlation be-
tween PRL level and disease activity, serum PRL levels were higher in
patientswith greater PDAI. Thatmay be explained by the PRL and im-
mune system relations. Nevertheless, a stress induced increase in PRL
levels might be a confounding factor.
In this study, PRL was measured only in new patients before
starting therapy with corticosteroids or immunomodulatory medica-
tions. Further studies can be done on changes on PRL level with dis-
ease progression and/or after treatment.
PRL levels were measured before starting of steroids and immu-
nomodulatory drugs.
Literature reviews demonstrate the immunomodulatory effect of
PRL, and further studies need to stabilize PRL levels screening values
as a prognostic factor.Conclusion
In our study, higher than normal serum prolactin levels were de-
tected in patients with greater PDAI. Although it did not reach statis-
tical signiﬁcance, its consistency with other studies can further
demonstrate PRL immunomodulatory effects.Acknowledgements
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